vs
Amneal Pharmaceuticals, Inc.（AMRX）与Sunrun Inc.（RUN）财务数据对比。点击上方公司名可切换其他公司
Sunrun Inc.的季度营收约是Amneal Pharmaceuticals, Inc.的1.4倍（$1.2B vs $814.3M），Sunrun Inc.净利率更高（8.9% vs 4.3%，领先4.6%），Sunrun Inc.同比增速更快（123.5% vs 11.5%），过去两年Sunrun Inc.的营收复合增速更高（59.0% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Sunrun Inc.是美国知名的光伏系统及电池储能产品供应商，业务以服务住宅客户为主，2007年成立，总部位于加利福尼亚州旧金山，致力于为家庭用户提供高效的清洁能源解决方案。
AMRX vs RUN — 直观对比
营收规模更大
RUN
是对方的1.4倍
$814.3M
营收增速更快
RUN
高出112.0%
11.5%
净利率更高
RUN
高出4.6%
4.3%
两年增速更快
RUN
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.2B |
| 净利润 | $35.1M | $103.6M |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | 8.4% |
| 净利率 | 4.3% | 8.9% |
| 营收同比 | 11.5% | 123.5% |
| 净利润同比 | 212.9% | 103.7% |
| 每股收益（稀释后） | $0.10 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRUN
| Q4 25 | $814.3M | $1.2B | ||
| Q3 25 | $784.5M | $724.6M | ||
| Q2 25 | $724.5M | $569.3M | ||
| Q1 25 | $695.4M | $504.3M | ||
| Q4 24 | $730.5M | $518.5M | ||
| Q3 24 | $702.5M | $537.2M | ||
| Q2 24 | $701.8M | $523.9M | ||
| Q1 24 | $659.2M | $458.2M |
净利润AMRXRUN
| Q4 25 | $35.1M | $103.6M | ||
| Q3 25 | $2.4M | $16.6M | ||
| Q2 25 | $22.4M | $279.8M | ||
| Q1 25 | $12.2M | $50.0M | ||
| Q4 24 | $-31.1M | $-2.8B | ||
| Q3 24 | $-156.0K | $-83.8M | ||
| Q2 24 | $6.0M | $139.1M | ||
| Q1 24 | $-91.6M | $-87.8M |
毛利率AMRXRUN
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
营业利润率AMRXRUN
| Q4 25 | 13.8% | 8.4% | ||
| Q3 25 | 9.0% | 0.5% | ||
| Q2 25 | 15.4% | -19.7% | ||
| Q1 25 | 14.4% | -22.8% | ||
| Q4 24 | 10.4% | -628.0% | ||
| Q3 24 | 12.6% | -23.8% | ||
| Q2 24 | 13.6% | -24.4% | ||
| Q1 24 | -1.6% | -40.0% |
净利率AMRXRUN
| Q4 25 | 4.3% | 8.9% | ||
| Q3 25 | 0.3% | 2.3% | ||
| Q2 25 | 3.1% | 49.1% | ||
| Q1 25 | 1.8% | 9.9% | ||
| Q4 24 | -4.3% | -542.7% | ||
| Q3 24 | -0.0% | -15.6% | ||
| Q2 24 | 0.9% | 26.5% | ||
| Q1 24 | -13.9% | -19.2% |
每股收益（稀释后）AMRXRUN
| Q4 25 | $0.10 | $0.38 | ||
| Q3 25 | $0.01 | $0.06 | ||
| Q2 25 | $0.07 | $1.07 | ||
| Q1 25 | $0.04 | $0.20 | ||
| Q4 24 | $-0.10 | $-12.59 | ||
| Q3 24 | $0.00 | $-0.37 | ||
| Q2 24 | $0.02 | $0.55 | ||
| Q1 24 | $-0.30 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | — |
| 总债务越低越好 | $2.6B | $14.7B |
| 股东权益账面价值 | $-70.8M | $3.1B |
| 总资产 | $3.7B | $22.6B |
| 负债/权益比越低杠杆越低 | — | 4.69× |
8季度趋势，按日历期对齐
现金及短期投资AMRXRUN
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | — | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — | ||
| Q1 24 | $46.5M | — |
总债务AMRXRUN
| Q4 25 | $2.6B | $14.7B | ||
| Q3 25 | $2.6B | $14.6B | ||
| Q2 25 | $2.2B | $14.0B | ||
| Q1 25 | $2.2B | $13.6B | ||
| Q4 24 | $2.4B | $12.9B | ||
| Q3 24 | $2.4B | $12.5B | ||
| Q2 24 | $2.4B | $12.0B | ||
| Q1 24 | $2.4B | $11.1B |
股东权益AMRXRUN
| Q4 25 | $-70.8M | $3.1B | ||
| Q3 25 | $-109.5M | $3.0B | ||
| Q2 25 | $-112.1M | $2.9B | ||
| Q1 25 | $-131.7M | $2.6B | ||
| Q4 24 | $-109.3M | $2.6B | ||
| Q3 24 | $-93.4M | $5.3B | ||
| Q2 24 | $-57.5M | $5.4B | ||
| Q1 24 | $-63.7M | $5.2B |
总资产AMRXRUN
| Q4 25 | $3.7B | $22.6B | ||
| Q3 25 | $3.6B | $22.2B | ||
| Q2 25 | $3.4B | $21.2B | ||
| Q1 25 | $3.4B | $20.4B | ||
| Q4 24 | $3.5B | $19.9B | ||
| Q3 24 | $3.5B | $22.1B | ||
| Q2 24 | $3.5B | $21.4B | ||
| Q1 24 | $3.5B | $20.8B |
负债/权益比AMRXRUN
| Q4 25 | — | 4.69× | ||
| Q3 25 | — | 4.90× | ||
| Q2 25 | — | 4.80× | ||
| Q1 25 | — | 5.19× | ||
| Q4 24 | — | 5.05× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | — | 2.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $96.9M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | — |
| 自由现金流率自由现金流/营收 | 13.3% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | 3.72× | 0.94× |
| 过去12个月自由现金流最近4个季度 | $269.9M | — |
8季度趋势，按日历期对齐
经营现金流AMRXRUN
| Q4 25 | $130.3M | $96.9M | ||
| Q3 25 | $118.5M | $-121.5M | ||
| Q2 25 | $83.8M | $-292.7M | ||
| Q1 25 | $7.4M | $-104.2M | ||
| Q4 24 | $118.1M | $-258.4M | ||
| Q3 24 | $141.8M | $-156.2M | ||
| Q2 24 | $39.7M | $-208.5M | ||
| Q1 24 | $-4.4M | $-143.1M |
自由现金流AMRXRUN
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | $-156.4M | ||
| Q2 24 | $29.0M | — | ||
| Q1 24 | $-13.6M | — |
自由现金流率AMRXRUN
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | -29.1% | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | -2.1% | — |
资本支出强度AMRXRUN
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | 0.0% | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.4% | — |
现金转化率AMRXRUN
| Q4 25 | 3.72× | 0.94× | ||
| Q3 25 | 50.00× | -7.33× | ||
| Q2 25 | 3.74× | -1.05× | ||
| Q1 25 | 0.61× | -2.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | -1.50× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RUN
| Products | $692.3M | 60% |
| Customer Agreements | $435.2M | 38% |
| Manufactured Product Other | $56.7M | 5% |
| Incentives | $31.3M | 3% |
